No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
Ready to participate?
Review the details below, then apply to join this clinical trial.
At a Glance
Age
15 and older
Sex
Any
Study type
Observational
Participants needed
200 (estimated)
Sponsor
Fondazione Italiana Linfomi - ETS · Other
Who this trial is looking for
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
This is an observational, multicenter, international and retrospective study, that aims to collect data on clinical and pathological characteristics, treatment regimens, outcome, and prognostic factors (clinical, biomarkers and/or radio-metabolic) in patients affected by PBL.
Trial Locations
Loading…
Loading trial locations…
Facility
City
State
Country
Status
Eligibility Criteria
Inclusion Criteria:
* Diagnosis of plasmablastic lymphoma (PBL) between Jan 1st 2000, and Dec 31st 2022
* Histologically confirmed plasmablastic lymphoma (PBL) diagnosis according to local pathological report
* Age \> 18 years old
* Availability of complete medical records
* Availability of histopa…
Inclusion Criteria:
* Diagnosis of plasmablastic lymphoma (PBL) between Jan 1st 2000, and Dec 31st 2022
* Histologically confirmed plasmablastic lymphoma (PBL) diagnosis according to local pathological report
* Age \> 18 years old
* Availability of complete medical records
* Availability of histopathological material requested by the study
Exclusion Criteria:
* Any other histology than PBL
* Lack of complete medical records
* Lack of histopathological material requested by the study
Picking one helps us show the most relevant trials first.
Your results are loading in the background — you can
change this any time from the results page.
Set your location to continue
Find My Trials uses your location to surface clinical trials near you.
Add your city or zip code to your profile and try again.